CSPC Pharmaceutical Group’s Stock Price Drops to 7.62 HKD, Reflecting a 1.04% Decrease: Market Update

CSPC Pharmaceutical Group (1093)

7.62 HKD -0.08 (-1.04%) Volume: 99.17M

CSPC Pharmaceutical Group’s stock price currently stands at 7.62 HKD, experiencing a slight dip this trading session with a percentage change of -1.04%. Despite the drop, the company maintains a robust trading volume of 99.17M and showcases a promising percentage change YTD of +61.09%, highlighting its strong market performance and potential for growth.

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group‘s stock price is likely to see movement today following the announcement that its SYH2056 tablets have obtained clinical trial approval in the U.S. This milestone comes shortly after the company’s antidepressant drug also gained approval for trials by the U.S. FDA. These developments signal a positive outlook for CSPC Pharmaceutical Group as it continues to expand its presence in the pharmaceutical market and advance its pipeline of innovative drugs. Investors are keeping a close eye on the company as these key events unfold, potentially impacting stock performance in the near future.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, such as Tina Banerjee, have been closely following CSPC Pharmaceutical Group‘s performance. In a recent report titled “CSPC Pharma (1093 HK): 9M25 Remain Subdued on Finished Drugs; Key Pivotal Data Read Outs Awaited,” it was noted that the company’s revenue dropped by 12% YoY due to a decline in finished drugs sales. Despite this, the company managed to compensate with bulk products and license fees. Analysts believe that focusing on new products and the high-end market will be crucial for future growth as pivotal data read outs are awaited.

In another report by Tina Banerjee, titled “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” it was highlighted that CSPC Pharmaceutical Group‘s revenue dropped by 18.5% YoY in the first half of 2025 due to lower finished drug sales. However, analysts remain optimistic about future revenue visibility with upcoming collaborations and expansion into the high-end market. The anticipation of more licensing deals in the second half of 2025 bodes well for the company’s future growth prospects.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a positive long-term outlook. The company scores high in areas such as Dividend and Resilience, indicating strong performance in these aspects. With a solid Value score as well, investors may find CSPC Pharmaceutical Group to be a promising investment opportunity.

CSPC Pharmaceutical Group Limited, a company known for manufacturing and selling pharmaceutical products including vitamin C, antibiotics, and generic drugs, also shows potential for growth with a moderate score in that category. Additionally, the company’s Momentum score suggests a level of stability and consistency in its performance. Overall, CSPC Pharmaceutical Group appears to be a well-rounded company with a promising future in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma